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A B S T R A C T
Background
Preterm birth is a major cause of perinatal mortality and morbidity. Cyclo-oxygenase (COX) inhibitors inhibit uterine contractions,
are easily administered and have fewer maternal side-effects compared to conventional tocolytics. However, adverse effects have been
reported on the fetus and newborn as a result of exposure to COX inhibitors.
Objectives
To assess the effects on maternal, fetal and neonatal outcomes of COX inhibitors administered as a tocolytic agent to women in preterm
labour when compared with (i) placebo or no intervention and (ii) other tocolytics. In addition, to compare the effects of non-selective
COX inhibitors with COX-2 selective inhibitors.
Search methods
We searched the Cochrane Pregnancy and Childbirth Group’s Trials Register (August 2004). We also contacted recognised experts
and cross referenced relevant material. We updated the search of the Cochrane Pregnancy and Childbirth Group’s Trials Register on 1
October 2009 and added the results to the awaiting classification section.
Selection criteria
All published and unpublished randomised trials in which COX inhibitors were used for tocolysis for women in labour between 20
and 36 completed weeks’ gestation.
Data collection and analysis
Three authors independently evaluatedmethodological quality and extracted data.We sought additional information from trial authors.
Main results
This review includes outcome data from 13 trials with a total of 713 women. The non-selective COX inhibitor, indomethacin was
used in 10 trials. When compared with placebo, COX inhibition (indomethacin only) resulted in a reduction in birth before 37 weeks’
gestation (relative risk (RR) 0.21; one trial, 36 women), an increase in gestational age (weighted mean difference (WMD) 3.53 weeks)
and birthweight (WMD 716.34 gm; two trials, 67 women). Compared to any other tocolytic, COX inhibition resulted in a reduction
in birth before 37 weeks’ gestation (RR 0.53; three trials, 168 women) and a reduction in maternal drug reaction requiring cessation
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of treatment (RR 0.07; five trials and 355 women). A comparison of non-selective COX inhibitors versus any COX-2 inhibitor (two
trials, 54 women) did not demonstrate any differences in maternal or neonatal outcomes.
Due to small numbers, all estimates of effect are imprecise and need to be interpreted with caution. Potential adverse effects of COX
inhibition on the fetus, newborn or mother could not be adequately assessed due to insufficient data.
Authors’ conclusions
There is insufficient information on which to base decisions about the role of COX inhibition for women in preterm labour. Further
well designed trials are needed.
[Note: The 11 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.]
P L A I N L A N G U A G E S U M M A R Y
Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Not enough evidence on whether cyclo-oxygenase (COX) inhibitors administered to women in threatened premature labour may
reduce the risk of babies being born too early.
Babies born too early are at increased risk of serious illness, and often do not survive. COX inhibitors inhibit uterine contractions, so
may postpone birth to allow the administration of steroids to the mother to help mature the baby’s lungs. COX inhibitors may have
adverse effects on the baby’s heart, lungs and kidneys, and on the mother. Other drugs given for premature labour also have side-effects.
This review found that COX inhibitors may be better than no treatment, or other drugs, in reducing the number of babies born too
early; however, there is insufficient evidence on possible adverse effects.
B A C K G R O U N D
Pretermbirth, defined as birth occurring between 20 and 36 weeks
of gestation is a major contributor to perinatal mortality and mor-
bidity. It affects approximately 6% to 7% of births in high-income
countries (Lumley 1993). Of all perinatal deaths, approximately
75% occur in preterm infants although in many cases the fetus is
either dead at the onset of preterm labour or lethally malformed
(Keirse 1989). About two thirds of preterm births results from
spontaneous preterm labour or preterm rupture of themembranes,
the remainder are due to iatrogenic early delivery for maternal or
fetal indications (Mercer 1996). The birth of a preterm infant who
requires intensive care for its survival is a crisis, not only for the
infant, but also for the parents (McCain 1993).
Little progress has been made over the last two decades in reduc-
ing the incidence of preterm birth, but benefits may result from
short-termprolongation of pregnancy to enablematernal corticos-
teroids to be administered (Crowley 1996) and/or in utero transfer
to a centre with neonatal intensive care facilities (Powell 1995).
A range of pharmacological agents (tocolytics) have been used to
inhibit preterm labour in order to allow time for such co-inter-
ventions to occur (short-term tocolytic therapy). Maintenance to-
colytic therapy, used to prevent recurrence of preterm labour after
an initial course of successful treatment, has not been shown to
improve perinatal outcomes or effectively prolong pregnancy and
is not widely used (Sanchez-Ramos 1999). The role of mainte-
nance therapy for women following threatened preterm labour is
not addressed in this review.
A range of tocolytic agents have been used to inhibit preterm
labour and postpone preterm birth (and are the topics of other
Cochrane systematic reviews) including nitric oxide donors (glyc-
eryl trinitrate) (Duckitt 2002), calcium channel blockers (com-
monly nifedipine) (King 2003), betamimetics (Anotayanonth
2004), magnesium sulphate (Crowther 2002), oxytocin recep-
tor antagonists (Papatsonis 2003) and cyclo-oxygenase (COX) in-
hibitors.
The tocolytic agents that have been most thoroughly evaluated are
the betamimetics (ritodrine, salbutamol and terbutaline). These
are effective in delaying delivery for up to 48 hours (Anotayanonth
2004), although no impact has been shown on perinatal mortality
or morbidity (Anotayanonth 2004; Gyetvai 1999; King 1988).
Betamimetic drugs have a high frequency of unpleasant, some-
times severe maternal side-effects including tachycardia, hypoten-
2Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sion, tremulousness and a range of biochemical disturbances. Be-
tamimetics have also been linked to maternal death from pul-
monary oedema (Keirse 1989). In a recent Cochrane review, cal-
cium channel blockers have been suggested as safe and marginally
more effective when compared to betamimetics with a lower in-
cidence of maternal adverse side-effects and lower neonatal mor-
bidity (King 2003).
Prostaglandins have an important role in the onset and mainte-
nance of labour (Keirse 1992). COX enzymes are fundamental
to the production of prostaglandins and inhibitors reduce uter-
ine contractions (Doret 2002; Van den Veyver 1993). COX in-
hibitors are easily administered (orally or rectally) and have fewer
maternal side-effects than betamimetics (Babay 1998). COX in-
hibitors, however, freely cross the placenta and can interfere with
prostaglandinhomeostasis in the fetus (Moise 1990). Reports from
case series have attributed a range of adverse effects in the fe-
tus and neonate to in utero exposure to indomethacin (the most
commonly used COX inhibitor) during tocolysis (Eronen 1994;
Norton 1993; Souter 1998). These reported adverse effects in-
clude oligohydramnios, renal failure, premature closure of the duc-
tus arteriosus with consequent pulmonary hypertension, persis-
tent patent ductus arteriosus, necrotising enterocolitis, and intra-
ventricular haemorrhage.
The recognition of distinct forms of COX, namely COX-1 and
COX-2, led to the development of COX-2 specific inhibitors.
COX-2 is specifically associated with myometrial contractility. It
is possible that selective inhibition could enable more effective
tocolysis with reduced adverse events.
This review outlines the evidence of benefit and harm to the
mother and infant from short-term administration of COX in-
hibitors in threatened preterm labour.
O B J E C T I V E S
1. To assess the effects on maternal, fetal and neonatal
outcomes of cyclo-oxygenase (COX) inhibitors administered as a
tocolytic agent to women in preterm labour when compared
with either placebo or no intervention.
2. To assess the effects on maternal, fetal and neonatal
outcomes of COX inhibitors administered as a tocolytic agent to
women in preterm labour when compared with other tocolytic
agents.
3. To assess the effects on maternal, fetal and neonatal
outcomes of non-selective COX inhibitors administered as a
tocolytic agent to women in preterm labour when compared
with COX-2 selective inhibitors.
4. To undertake subgroup analyses where sufficient data are
available, as follows:
• women receiving treatment commenced before 28 weeks’
gestation versus 28 weeks and above;
• women with a multiple pregnancy versus women with a
singleton pregnancy;
• women with ruptured membranes versus women with
intact membranes;
• type of tocolytic agent, specifically COX inhibitors
compared with: betamimetics, magnesium sulphate, calcium
channel blockers and with oxytocin receptor antagonists;
• high-quality versus low-quality trials (high-quality trials are
defined as trials which employed an adequate method for
blinding of randomisation and intervention - please see ’Methods
of the review’ for further details).
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomised trials, in which cyclo-
oxygenase (COX) inhibitors were used for tocolysis in the man-
agement of preterm labour, will be eligible.
Types of participants
Women assessed as being in preterm labour (i.e. between 20 and
36 completed weeks of gestation), and suitable for tocolysis.
Types of interventions
COX inhibitors, administered by any route, in the management
of women in preterm labour.
Types of outcome measures
Primary outcomes
1. Death or major sensorineural disability at two years of age
(defined as any one or more of the following: legal blindness,
sensorineural deafness requiring hearing aids, moderate or severe
cerebral palsy or developmental delay/intellectual impairment
(defined as developmental quotient or intelligence quotient less
than two standard deviations below the mean)).
2. Extremely preterm birth (less than 28 weeks’ gestation).
3. Birth less than 48 hours after trial entry.
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4. Serious maternal outcome (defined as death, cardiac arrest,
respiratory arrest, admission to intensive care unit).
Secondary outcomes
Maternal
Adverse drug reaction
Cessation of treatment for maternal adverse drug reaction
Oligohydramnios
Pregnancy prolongation (interval between randomisation and de-
livery)
Complete course of antenatal steroids
Antepartum haemorrhage
Postpartum haemorrhage
Need for blood transfusion
Mode of delivery
Length of postnatal hospital stay
Length of antenatal hospital stay
Satisfaction with the therapy
Infant
Premature closure of the ductus arteriosus
Birth within seven days of treatment
Birth within 48 hours of treatment
Birth before 28 completed weeks
Birth before 34 completed weeks
Birth before 37 completed weeks
Gestation at birth
Birthweight
Birthweight less than the third centile for gestational age
Birthweight less than 2500 grams
Apgar score of less than seven at five minutes
Pulmonary hypertension
Renal failure
Respiratory distress syndrome
Use of mechanical ventilation
Duration of mechanical ventilation
Intraventricular haemorrhage
Intraventricular haemorrhage - Grade III or IV
Periventricular leukomalacia
Retinopathy of prematurity
Retinopathy of prematurity - Grades III or IV
Chronic lung disease
Necrotising enterocolitis
Chronic lung disease
Neonatal sepsis
Fetal death
Neonatal death
Admission to neonatal intensive care unit
Neonatal length of hospital stay
Long-term neurodevelopmental status - 18 months to two years
of age
Search methods for identification of studies
Electronic searches
We searched the Cochrane Pregnancy and Childbirth Group’s Tri-
als Register by contacting the Trials Search Co-ordinator (August
2004). We updated this search on 1 Ocotber 2009 and added the
results to Studies awaiting classification.
The Cochrane Pregnancy and Childbirth Group’s Trials Register
is maintained by the Trials Search Co-ordinator and contains trials
identified from:
1. quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE;
3. handsearches of 30 journals and the proceedings of major
conferences;
4. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Details of the search strategies for CENTRAL and MEDLINE,
the list of handsearched journals and conference proceedings, and
the list of journals reviewed via the current awareness service can
be found in the ‘Specialized Register’ section within the edito-
rial information about the Cochrane Pregnancy and Childbirth
Group.
Trials identified through the searching activities described above
are each assigned to a review topic (or topics). The Trials Search
Co-ordinator searches the register for each review using the topic
list rather than keywords.
Searching other resources
In addition, the review authors sought ongoing and unpublished
trials by contacting experts in the field.
We did not apply any language restrictions.
Data collection and analysis
We used the standard methods of the Cochrane Collaboration
(Alderson 2004a). Three review authors (James King, Vicki Fle-
nady, Steve Cole) independently selected trials for inclusion, ex-
tracted data and assessed methodological quality. Differences were
resolved by discussion.
Quality assessment
Four major sources of potential bias and methods for avoidance of
these biases were considered in the assessment of trial quality: (1)
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selection bias - blinding of randomisation, (2) performance bias -
blinding of intervention, (3) attrition bias - completeness of follow
up, (4) detection bias - blinding of outcome assessment. A quality
rating for blinding of randomisation was assigned to each trial,
using the criteria outlined in the Cochrane Reviewers’ Handbook
(Alderson 2004b): (A) adequate, (B) unclear, (C) inadequate, or
(D) not used. A quality rating of (A) yes, (B) cannot tell, or (C)
no, was assigned to the other quality components (blinding of
intervention, completeness of follow up and blinding of outcome
assessment). High-quality trials were defined as those receiving an
A rating for the criterion of blinding of randomisation (central
computerised randomisation service or sealed opaque envelopes)
and for blinding of the intervention (use of a placebo).
Data management and analysis
We used the Review Manager software (RevMan 2003) for data
management and analysis. We sought missing data from the in-
vestigators of one included trial (McWhorter 2004) in order to
perform analyses on an intention-to-treat basis. One trial (Sawdy
2003) compared three cyclo-oxygenase (COX) inhibitors: in-
domethacin, nimesulide and sulindac. We included this trial in
the comparison of selective versus non-selective COX inhibitors
combining the indomethacin and sulindac treatment groups. For
individual trials, mean differences (and 95% confidence intervals)
are reported for continuous variables. For categorical outcomes,
the relative risk and risk difference (and 95% confidence inter-
vals) are reported. For the meta-analysis, where possible, weighted
mean differences (and 95% confidence intervals) are reported for
continuous variables, and the relative risk (and 95% confidence
intervals) for categorical outcomes. The number needed to treat
is presented where appropriate.
Meta-analysis and heterogeneity
Weconducted themeta-analysis using the fixed-effectmodel for all
outcomes except in the comparison of COX inhibitors compared
with placebo (two trials (Panter 1999;Zuckerman1984) including
70 women) for the outcome delivery within 48 hours and seven
days of initiation of treatment. For these outcomes, a random-
effectsmodel was used to address statistical heterogeneity (Higgins
2002). Application of a random-effects model resulted in a loss of
statistical significance for both outcomes which was shown when
applying a fixed-effect model. In these two small trials, the review
authors agreed that there was some clinical heterogeneity. One
trial (Panter 1999) included twin pregnancies and used a lower
dosage regimen of indomethacin (50 mg initial dose then 25 mg
six hourly) and the other trial, showing a greater benefit in terms of
these outcomes, (Zuckerman 1984) enrolled only singletons and
used a higher dose of indomethacin (100 mg with an option of an
additional 100 mg then 25 mg six hourly). However, we decided
that it was reasonable to combine these outcomes using a random-
effects model as the studies were reasonably clinically comparable
and on visual inspection of the graphs the individual trial effects
were in the same direction with overlapping confidence intervals.
We assessed the presence of statistical heterogeneity in subgroup
analyses according to the method described by Deeks 2004 which
is based on the heterogeneity chi-squared statistic calculated in
RevMan 2003.
We conducted subgroup analyses within the comparison of COX
inhibitors compared to other tocolytic agents according to type of
other tocolytic used, i.e. betamimetics and magnesium sulphate.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Fifty-seven publications were identified as potentially eligible for
inclusion. Of these, 13 trials (involving 24 publications) were ex-
cluded. A further four are awaiting assessment pending additional
information from the authors (Castillo 1988; Nevils 1994; Odeh
1997; Purwaka 2004). Therefore, this review includes thirteen
randomised trials (involving 29 publications) testing the effects
of cyclo-oxygenase (COX) inhibitors for tocolysis for women in
preterm labour. (Seven reports from an updated search in October
2009 have been added to Studies awaiting classification.)
Please see table, Characteristics of excluded studies for reasons for
exclusion.
Included studies
A total of 713 women participated in the 13 included trials (
Besinger 1991; Kramer 1999; Kurki 1991; McWhorter 2004;
Morales 1989; Morales 1993; Niebyl 1980; Panter 1999; Parilla
1997; Sawdy 2003; Schorr 1998; Stika 2002; Zuckerman 1984).
Participants
The participants included in these trials were reasonably homoge-
neous. In eight trials the gestational age at inclusion ranged from
a minimum of 23 to 25 weeks to a maximum of 32 to 35 weeks
(Besinger 1991; Kramer 1999; Kurki 1991; McWhorter 2004;
Niebyl 1980; Sawdy 2003; Stika 2002; Zuckerman 1984). In five
trials, the gestation at inclusion ranged from less than 30 to less
than 34 with no lower limit being specified. Preterm labour was
reasonably consistently defined across the trials, most excluding
thosewomenwith a cervical dilatation of greater than4 cm.Twelve
trials reported the exclusion of women with preterm premature
rupture of membranes; Morales 1993 did not report whether this
was an exclusion criterion. Seven trials included women with a
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multiple pregnancy (Besinger 1991; McWhorter 2004; Morales
1989; Niebyl 1980; Panter 1999; Parilla 1997; Schorr 1998) with
three of these excluding higher order multiples (Niebyl 1980;
Panter 1999; Schorr 1998). The standard contraindications for
tocolysis were reported as exclusion criteria in the majority of
included trials, i.e. fetal distress, chorioamnionitis, severe pre-
eclampsia/eclampsia, abruptio placentae or contraindications to
non-steroidal anti-inflammatory agents.
Tocolysis
Ten of the thirteen trials used the COX inhibitor indomethacin.
Indomethacin dosing regimens were similar across the trials with
loading doses of 50 to 100 mg (mostly given rectally) followed by
25 to 50 mg orally every four to six hours for 24 to 48 hours. One
trial (Sawdy 2003) administered indomethacin 200 mg rectally
every 12 hours for up to 48 hours. Three trials administered an
additional 100 mg loading dose of indomethacin if contractions
persisted (Morales 1989; Morales 1993; Zuckerman 1984). The
COX inhibitors used in the remaining three trials were: nime-
sulide, sulindac, ketorolac and rofecoxib. Eight trials compared
COX inhibitors with other tocolytic agents. Four trials compared
with betamimetic agents (two ritodrine, one terbutaline and one
nylidrin) and four with magnesium sulphate. Two small trials
(Sawdy 2003; Stika 2002) compared non-selective with selective
COX inhibitors. One trial (Stika 2002) compared indomethacin
with theCOX-2 inhibitor celecoxib and the other compared sulin-
dac and indomethacin with nimesulide (Sawdy 2003). Five trials
reported the use maintenance tocolysis. The gestation at which
maintenance treatment was used (reported in three trials only)
ranged from 35 to 37 weeks. Eight trials reported using alternative
tocolytics after failure of the study treatment (rescue tocolysis),
although details on the tocolytics used were largely not reported.
Antenatal corticosteroids
Nine trials reported a protocol for administration of antenatal
corticosteroids for all women enrolled; in the remaining four trials
antenatal corticosteroid use was not reported.
Outcomes
No outcome data were available in any of the included trials for
two of the four prespecified primary outcome measures for this
review: death or major sensorineural disability at two years of age
and extremely preterm birth (less than 28 weeks’ gestation). Four
trials reported data for the prespecified primary outcome measure
of birth less than 48 hours after initiation of treatment. There was
limited reporting for the remaining primary outcome of serious
maternal outcome (defined as death, cardiac arrest, respiratory ar-
rest, admission to intensive care unit). Although five trials reported
maternal adverse drug reactions requiring cessation of treatment,
other potential adverse effects such as antepartum and postpartum
haemorrhage were reported in only two trials.
Reporting of other prespecified fetal and neonatal outcomes is as
follows: perinatal mortality (reported in eight of the thirteen in-
cluded trials); respiratory distress syndrome (nine trials), persistent
pulmonary hypertension of the newborn (seven trials), intraven-
tricular haemorrhage (six trials), premature closure of the ductus
arteriosis (nine trials), oligohydramnios (five trials), neonatal re-
nal failure (one trial). Clear definitions of outcome measures were
often lacking in the trial reports.
Please see table, Characteristics of included studies for further de-
tails.
Risk of bias in included studies
The majority of the included trials were considered to be of high
quality. Twelve of the thirteen included trials reported adequate
concealment of random allocation to treatment (A quality rating).
In one trial, the precise method of random allocation to treatment
was not described (Zuckerman 1984). Blinding of the interven-
tion and outcome assessment was reported in eight trials (Kramer
1999; Kurki 1991; McWhorter 2004; Niebyl 1980; Panter 1999;
Sawdy 2003; Stika 2002; Zuckerman 1984). However, in one trial
(McWhorter 2004), themethod used for blinding of the interven-
tion is considered suboptimal as differences in dosing regimens for
the two study groups rendered the allocation potentially identifi-
able.
In this review, an attempt was made to conduct an intention-
to-treat analyses for all outcomes. Four trials had postrandomisa-
tion exclusions (Besinger 1991; McWhorter 2004; Morales 1993;
Niebyl 1980). In three trials, the rates of exclusions were gener-
ally low (range 7% to 11%) and not considered by the authors
of this review to be a threat to its validity. However, in one trial
(McWhorter 2004) outcome data were not available for 36 (16%)
infants, 21 in the rofecoxib arm and 15 infants in the magnesium
sulphate (MgSO4). The losses included outcomes for the second
twin in a multiple pregnancy (eight in each study group) as only
outcomes for twin onewere reported. In addition, outcomes for 13
singletons in the rofecoxib and seven in the magnesium sulphate,
were not available due to loss to follow up. As the exclusions, in-
cluding multiple births, were fairly evenly distributed across the
study groups we considered the threat of bias to be low. The trial
investigators were contacted for missing data, however at the time
of this review data were unavailable.
Please see table of Characteristics of included studies for further
details.
Effects of interventions
This review includes outcomes data from 13 trials with a total
of 713 women. Due to small numbers, all estimates of effect are
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therefore imprecise and need to be interpretedwith caution. Three
comparisons were undertaken: any cyclo-oxygenase (COX) in-
hibitor versus placebo, COX inhibitor versus any other tocolytic
and any non-selective COX inhibitor versus any COX-2 inhibitor.
Any COX inhibitors versus placebo
This comparison includes three trials (Niebyl 1980; Panter 1999;
Zuckerman 1984) with a total of 106 women. When compared
with placebo, COX inhibition (indomethacin only) resulted in a
statistically significant reduction in the numbers ofwomen deliver-
ing less than 37 weeks’ gestation (relative risk (RR) 0.21; 95% con-
fidence interval (CI) 0.07 to 0.62 (number needed to treat (NNT)
2; 95% CI 1 to 3)) in one small trial of 36 women (Zuckerman
1984). An increase in gestational age at birth ((weighted mean
difference (WMD) 3.53 weeks; 95% CI 1.13 to 5.92) and birth-
weight (WMD 716.34 gm; 95% CI 425.52 to 1007.16) was also
shown (two trials 0f 67 women: Niebyl 1980; Zuckerman 1984).
Data from two trials (Panter 1999; Zuckerman 1984) including
70 women showed a trend towards a reduction in delivery within
48 hours of initiation of treatment (RR 0.20; 95% CI 0.03 to
1.28) and within seven days (RR 0.41; 95% CI 0.10 to 1.66)
(random-effects model). No differences were detected in any other
reported outcomes including: perinatal mortality, respiratory dis-
tress syndrome, premature closure of the ductus and persistent
pulmonary hypertension of the newborn (reported by all trials);
intraventricular haemorrhage (one trial of 38 infants) or neona-
tal renal failure (one trial of 20 infants). One trial of 34 women
(Panter 1999) showed a trend towards more postpartum haemor-
rhage for women treated with COX inhibitors (RR 3.94; 95% CI
0.95 to 16.29).
COX inhibitors versus any other tocolytic
This comparison includes eight trials (Besinger 1991; Kramer
1999; Kurki 1991; McWhorter 2004; Morales 1989; Morales
1993; Parilla 1997; Schorr 1998) with a total of 557 women. In
three trials (Kramer 1999; Kurki 1991; Schorr 1998) including
168 women, COX inhibition when compared to any other to-
colytic resulted in a reduction in number of women delivering
prior to 37 weeks’ gestation (RR 0.53; 95%CI 0.31 to 0.94 (NNT
8; 95% CI 4 to 50)), a reduction in maternal drug reaction (RR
0.22; 95% CI 0.15 to 0.33 (seven trials and 629 women)) and
maternal drug reaction requiring cessation of treatment (RR 0.07;
95% CI 0.02 to 0.29 (NNT 7; 95% CI 5 to 10) (five trials and
355 women)).
No differences were detected in any other reported maternal or
neonatal outcomes. A trend towards a reduction in the number
of women delivering before 48 hours after initiation of treatment
was shown for women receiving COX inhibitors (RR 0.59; 95%
CI 0.34 to 1.02 (four trials and 415 women)). No difference was
shown in the number of women delivering within seven days (two
trials and 146 women). There was a trend towards an increase in
oligohydramnios for women receiving COX inhibitors (RR 2.53;
95% CI 0.76 to 8.46 (three trials including 295 women)). No dif-
ferences were detected in the following fetal or neonatal outcomes:
perinatal mortality (eight trials including 696 infants); respira-
tory distress syndrome (six trials and 403 infants); intraventricular
haemorrhage (seven trials and 548 infants); necrotising enterocol-
itis (NEC) (four trials including 298 infants); premature closure
of the ductus (four trials and 337 infants); persistent pulmonary
hypertension of the newborn (PPHN) (six trials and 490 infants)
although trends towards increased NEC and PPHN were shown
for infants of mothers receiving COX inhibitors.
Non-selective COX inhibitors versus any COX-2
inhibitor
A comparison of non-selective COX inhibitors (indomethacin and
nimesulide) versus any COX-2 inhibitor (two trials of 54 women:
Sawdy 2003; Stika 2002) showed no differences in any reported
maternal or neonatal outcomes.
Subgroup analysis: COX inhibitors compared with
betamimetics and with magnesium sulphate
Two subgroup analyses by type of tocolytic comparison groups
were undertaken, i.e. COX inhibitors compared with betamimet-
ics (four trials including 229 women: Besinger 1991; Kramer
1999; Kurki 1991; Morales 1989) and COX inhibitors com-
pared with magnesium sulphate (four trials including 328 women:
McWhorter 2004;Morales 1993; Parilla 1997; Schorr 1998). The
only statistically significant heterogeneity evident for outcomes
across these subgroup analyses was maternal adverse drug reaction.
COX inhibition compared with betamimetics resulted in a greater
reduction inmaternal adverse drug reactions thanCOX inhibition
compared with magnesium sulphate (P value 0.02). A marginal
difference was shown for the outcome of delivery within 48 hours
of initiation of treatment. COX inhibition when compared with
betamimetic agents resulted in a borderline statistically significant
reduction in the number of women delivering within 48 hours of
initiation of treatment (RR 0.27; 95% CI 0.08 to 0.96 (two trials
including 100 women)). However, statistically significant hetero-
geneity for this outcome was not evident (P value 0.24).
Due to small numbers, all estimates of effect are imprecise and
therefore need to be interpreted with caution. Potential adverse
effects of COX inhibition on the fetus, newborn or mother could
not be adequately assessed due to insufficient data. Also due to
insufficient data, the planned subgroup analyses (treatment com-
menced before 28 weeks’ gestation; and trials enrolling women
with a multiple pregnancy) could not be performed.
D I S C U S S I O N
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The results of this review including twelve, largely high-quality
trials involving 683 women indicate some benefit for cyclo-oxyge-
nase (COX) inhibitors in terms of pregnancy prolongation and also
fewer maternal side-effects than betamimetics. When compared
to placebo, COX inhibitors reduced the proportion of women de-
livering preterm (less than 37 weeks), increased birthweight, and
showed a trend towards a reduction in the incidence of delivery
within 48 hours and within seven days. Because these conclusions
are based on very small numbers (one study with 36 participants
and two studies with 67 participants), they must be interpreted
with caution. Despite these beneficial findings, COX inhibitors
were not associated with improvements in neonatal mortality or
any markers of neonatal morbidity. Again this finding must be in-
terpreted with caution. There are only three studies (Niebyl 1980;
Panter 1999; Zuckerman 1984) comparing COX inhibition with
placebo, with a total of 106 participants. Two of these studies
(Niebyl 1980; Zuckerman 1984) included participants up to 35
weeks’ gestation, when the incidence of neonatal adverse events
is low. The small number of adverse events reported allows no
meaningful conclusion to be drawn.
Compared to any other tocolytic, COX inhibitors were again as-
sociated with a decrease in the proportion of women delivering
at less than 37 weeks’ gestation, and a trend to a reduction in the
proportion of women delivering less than 48 hours from initi-
ation of treatment. Similar to the placebo comparison, no ben-
efit in terms of neonatal outcomes was shown for COX inhibi-
tion. Two small trials compared the selective COX inhibitors (ro-
fecoxib and nimesulide) with non-selective COX inhibitors (in-
domethacin and sulindac). No differences were shown in any re-
ported maternal or neonatal outcomes and due to small num-
bers of women enrolled in these trials (54), no conclusions can be
drawn on the relative benefits of selective COX inhibition.
This review was limited by small numbers for many outcomes
and the problem of different reporting techniques across the trials
caused significant difficulty in data analysis. Consistency in the
measurement and reporting of outcomes is an area that warrants
closer attention in the future conduct of tocolytic trials.
Amajor clinical issue regarding the use of COX inhibitors has been
concerned about possible effects on the fetal ductus arteriosus, in
particular, antenatal constriction and closure leading to postnatal
persistent patent ductus. In this review, a total of 403 women re-
ceived short-term tocolysis (up to 48 hours) with COX inhibitors
(mainly indomethacin) and there was only one case of antenatal
closure of the ductus arteriosus. There was no increase in the in-
cidence of patent ductus arteriosus postnatally (eight treated with
COX inhibitors versus eight treated with placebo or other tocolyt-
ics). These data suggest that, for short-term COX inhibition, the
concern about ductal effects of COX inhibitors may have been
overstated and with the benefits shown in this review (pregnancy
prolongation and lessmaternal adverse effects than betamimetics),
the role of COX inhibitors for women in preterm labour warrants
further attention.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is insufficient information on which to base decisions about
the value of cyclo-oxygenase (COX) inhibition for women in
preterm labour.
Implications for research
On the basis of the results of this review, further well-designed
placebo controlled trials are justified to assess the potential bene-
fits and safety of COX inhibition for women in preterm labour,
particularly addressing longer-term outcomes for infants and chil-
dren.
[Note: The 11 citations in the awaiting classification section of
the review may alter the conclusions of the review once assessed.]
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Besinger 1991
Methods Blinding of randomisation - yes.
Blinding of intervention - no.
Complete follow up - no.
3 women - 1 in indomethacin group and 2 in ritodrine group.
Blinding of outcome measure - cannot tell.
Participants 43 women 23-34 wks gestation in preterm labour defined as regular contractions with cervical change.
Singleton and multiple pregnancies
Exclusion criteria:
cervix > 4 cms dilated, ruptured membranes.
Interventions Intervention group:
indomethacin - load 50 mg po then 25-50 mg q4h until contractions ceased
Control group:
ritodrine 100-350 ug/min continued until 8-12 hours after contractions ceased
Both groups:
rescue tocolytic therapy:
yes - magnesium sulphate.
Maintenance tocolysis: yes - up to 35 weeks.
Indomethacin group - indomethacin po 4-6 hrly.
Ritodrine group - terbutaline po 2.5-5 mg 4-6 hrly.
Re treatment - yes.
Outcomes Maternal:
preterm birth < 35 wks.
Delivery within 48 hrs and 7 days.
Interval from treatment to delivery.
Adverse drug reaction.
Fetal/neonatal:
oligohydramnios, gestation at birth, birthweight, Apgar score, pulmonary hypertension, IVH, PDA,
duration of MV and nursery stay, perinatal death
Failed tocolysis defined as rupture of membranes, cervix > 5 cms, chorioamnionitis, oligohydramnios
Notes Antenatal corticosteroid use:
not reported.
Sample size calculation: not reported.
Postrandomisation exclusions: 3 women - 1 in indomethacin group for ’abruption soon after enrolment’
and 2 in ritodrine group for protocol violations
Risk of bias
Item Authors’ judgement Description
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Besinger 1991 (Continued)
Allocation concealment? Yes A - Adequate
Kramer 1999
Methods Blinding of randomisation - yes.
Blinding of intervention - yes.
Complete follow up - yes.
Blinding of outcome measure - yes.
Participants 20 women 24-35 wks in preterm labour defined as contractions 4 in 20 mins or 8 in 60, cervix greater
than 1 cm dilated and 40% effaced
Exclusion criteria:
maternal medical conditions, FGR, ruptured membranes, chorioamnionitis
Interventions Intervention group:
sulindac 200 mg q12h for 6 doses and placebo every 4 hours when not receiving active drug
Control group:
terbutaline 5 mg q4h for 72 hours.
Both groups:
rescue tocolytic therapy:
unknown.
Maintenance tocolysis: yes - both groups after 72 hours oral terbutaline until 36 weeks
Tocolysis for recurrent PTL.
Outcomes Maternal:
adverse drug reaction.
Fetal/neonatal:
main outcomes were fetal effects -
fetal urinary output, doppler evaluations of ductal, cerebral, umbilical and renal blood flow, AFI, preterm
birth
Notes Antenatal corticosteroid use: yes - all participants.
Sample size calculation: not reported.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Kurki 1991
Methods Blinding of randomisation - yes.
Blinding of intervention - yes.
Complete follow up -yes.
Blinding of outcome measure - yes.
Participants 60 women 25-34 wks in preterm labour defined as regular contractions at least every 10 mins and cervix
> 1 cm dilated
Exclusion criteria: ruptured membranes, multiple pregnancy, tocolysis this pregnancy, cervix > 4 cms
dilated, FGR, maternal sepsis or cardiovascular disease, aspirin allergy
Interventions Intervention group:
indomethacin loading dose rectal suppository 100 mg then 50 mg po q8h for 24 hrs and q8h up to 3
days plus IV placebo
Control group:
nylidrin IV 50 ug/min increased within 30 mins to 100-150 ug/min for maximum of 3 days
Both groups:
rescue tocolytic therapy:
not reported.
Maintenance tocolysis:
not reported.
Tocolysis for recurrent preterm labour: not reported.
Outcomes Maternal:
adverse drug reaction.
Fetal/neonatal:
preterm birth, treatment to delivery interval, GA at birth, birthweight, Apgar score, RDS, MV, sepsis,
NEC, IVH, death
Notes Antenatal corticosteroid use: not reported.
Sample size calculation: yes - details not reported.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
McWhorter 2004
Methods Blinding of randomisation - yes.
Blinding of intervention - yes but flawed - despite placebo treatment (both IV and oral) differences in the
IV regimens enabled identification of IV MgSO4 possible
Complete follow up - no.
Loss to follow up: 21 infants rofecoxib, and 15 infants MgSO4 (16%)
Blinding of outcome measure - yes (correspondence from authors)
Participants 214 women 22-34 wks in preterm labour defined as progressive cervical dilatation with regular contrac-
tions.
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McWhorter 2004 (Continued)
Singleton and multiple pregnancies included.
Exclusion criteria: ruptured membranes, cervix > 4 cms dilated, NRFS, FGR, fetal lethal abnormality,
allergy to NSAID, contraindications to tocolysis
Interventions Intervention group:
rofecoxib 50 mg po daily for 48 hrs plus intravenous saline at 80 ml/hr for 48 hrs
Control group: magnesium sulphate IV 4-6 g in 20% solution load then continuous infusion 2-4 g/hr
plus placebo oral capsule
Both groups:
rescue tocolysis: yes, no details.
Maintenance tocolysis: not reported.
Tocolysis for recurrent preterm labour: yes.
Outcomes Maternal:
adverse drug reaction, caesarean section, delivery with 48 hours, failure of tocolysis at 48 hrs
Fetal/neonatal: GA at birth, birthweight, Apgar score, RDS, admission to NICU, NICU stay, sepsis,
NEC, IVH, death, PPHN
Notes Antenatal corticosteroid use: yes.
Sample size calculation - yes based on delivery within 48 hrs of treatment
Postrandomisation exclusions includes the second twin in a multiple pregnancy (8 in each arm) as only
outcomes for twin one were included. In addition, outcome data were not included for 13 singletons in
the rofecoxib and 7 MgSO4 - reasons not given
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Morales 1989
Methods Blinding of randomisation - yes.
Blinding of intervention - no.
Complete follow up - yes.
Blinding of outcome measure - cannot tell.
Participants 106 women < 32 wks in preterm labour defined as regular contractions 4 in 20 mins with progressive
cervical dilatation or effacement. Singleton or multiple pregnancy
Exclusion criteria:
cervical dilatation > 4 cm, chorioamnionitis, medical complications contraindicating tocolysis, FGR,
major congenital abnormality
Interventions Intervention group:
indomethacin 100 mg suppository then 25 mg po q4h for 48 hrs. Additional suppository after 2 hrs if
required
Control group:
ritodrine IV 50 ug/min increasing by 50 ug/m every 20 mins until contractions stopped or a maximum
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Morales 1989 (Continued)
of 350 ug/min reached
Both groups:
rescue tocolytic therapy:
yes - IV magnesium sulphate.
Maintenance tocolysis: yes - terbutaline po.
Unknown duration.
Tocolysis for recurrent PTL: yes - as per study protocol.
Outcomes Maternal:
adverse drug reaction.
Fetal/neonatal: AFI, premature closure of ductus, delivery within 48 hrs and within 7 days, Apgar score,
birthweight, serum glucose, platelets, renal studies, pulmonary hypertension, PDA, RDS, IVH, perinatal
mortality
Cost.
Notes Antenatal corticosteroid use: yes.
Sample size calculation: not reported.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Morales 1993
Methods Blinding of randomisation - yes.
Blinding of intervention - no.
Complete follow up - no.
13 women excluded.
Blinding of outcome measure - cannot tell.
Participants 114 women < 32 wks in preterm labour defined as contractions 4 in 20 mins with progressive cervical
dilatation or effacement or cervical dilatation > 2 cm
Exclusion criteria:
multiple pregnancy, ruptured membranes, FGR, major congenital abnormalities, cervical dilatation > 4
cm
Interventions Intervention group:
indomethacin 100 mg rectal suppository then 25 mg po q4h for 48 hrs. Additional 100 mg suppository
if contractions persisted at 1-2 hrs
Control group:
magnesium sulphate IV 6 g load over 30 mins then 2 g/hr increasing up to 5 g/hr
Both groups:
rescue tocolytic therapy:
yes - details not reported.
Maintenance tocolysis: yes - terbutaline po 5 mg q6h. Unknown duration
Tocolysis for recurring preterm labour: unknown.
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Morales 1993 (Continued)
Outcomes Maternal:
caesarean section, adverse drug reaction.
Fetal/neonatal:
premature closure of ductus, delivery within 48 hrs, pregnancy prolongation, birthweight and GA, RDS,
pulmonary hypertension, IVH, perinatal mortality
Notes Antenatal corticosteroid use:
yes - all participants.
Sample size calculation:
not reported.
Postrandomisation exclusions: 13 women excluded - 7 indomethacin group and 6 MgSO4 due to failure
to follow study protocol
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Niebyl 1980
Methods Blinding of randomisation - yes.
Blinding of intervention - yes.
Complete follow up - no.
2 exclusions in the indomethacin group.
Blinding of outcome measure- yes.
Participants 32 women 24-25 wks in preterm labour defined as cervical dilatation of at least 2 cms or 75% effaced or
contractions with progressive cervical change. Singleton and twin pregnancies included
Exclusion criteria: higher ordermultiples, rupturedmembranes, cervical dilatation > 4 cms, FGR, salicylate
sensitivity
Interventions Intervention group:
indomethacin po 50 mg then 25 mg q4h for 24 hrs.
Control group:
placebo.
Both groups:
rescue tocolytic therapy - yes. Alcohol or isoxsuprine given if failed at 2 hrs
Maintenance tocolysis:
not reported.
Tocolysis for recurrent preterm labour-yes as per study protocol
Outcomes Maternal:
chorioamnionitis or endometritis, adverse drug reaction.
Fetal/neonatal:
premature closure of ductus, tocolytic failure - progressive cervical dilatation at 2 hours gestation at birth,
birthweight, RDS, pulmonary hypertension, jaundice, NEC, perinatal death
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Niebyl 1980 (Continued)
Notes Antenatal corticosteroid use: not reported.
Sample size calculation: not reported.
Postrandomisation exclusions: 2 exclusions in the indomethacin group - 1 due to vomiting and one did
not meet inclusion criteria (term)
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Panter 1999
Methods Blinding of randomisation - yes.
Blinding of intervention - yes.
Complete follow up - yes.
Blinding of outcome measure - yes.
Participants 34 women 23-30 wks in preterm labour defined as regular painful contractions with cervical dilatation.
Singleton and twin pregnancies included
Exclusion criteria: higher order multiples, ruptured membranes, FGR, chorioamnionitis, oligohydram-
nios, contraindications to indomethacin or tocolysis
Interventions Intervention group:
indomethacin 50 mg po then 25 mg q6h for 48 hrs.
Control group:
placebo.
Both groups:
rescue tocolytic therapy: not reported.
Maintenance tocolysis: not reported.
Tocolysis for recurrent preterm labour: not reported.
Outcomes Maternal:
endometritis, chorioamnionitis, antepartum and postpartum haemorrhage
Fetal/neonatal: fetal cardiac doppler studies, preterm birth < 37 wks, delivery within 48 hrs and 7 days,
premature closure of ductus, Apgar score, birthweight and GA, oliguria, pulmonary hypertension, RDS,
sepsis, IVH, NEC, CLD, perinatal death, duration of MV and hospital stay
Notes Antenatal corticosteroid use: yes - approx. 80%.
Sample size calculation: yes - 252 required based on combined perinatal mortality or severe neonatal
morbidity. Trial stopped early due to slow recruitment
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Parilla 1997
Methods Blinding of randomisation - yes - sealed envelopes.
Blinding of intervention -no.
Complete follow up - yes.
Blinding of outcome measure - cannot tell.
Participants 12 women < 30 wks in preterm labour defined as regular contractions with cervical change. Multiples
included
Exclusion criteria: ruptured membranes, FGR, chorioamnionitis, bleeding, abnormal fetal heart rate trace
Interventions Intervention group:
indomethacin 50-100 mg po or rectally then 25-50 mg po q4-6h for 24-48 hrs
Control group: magnesium sulphate IV 8 g load then 4 g over 2nd hr then 2.5 g/hr continued for 12 hrs
after contractions ceased
Both groups:
rescue tocolytic therapy:
yes - crossover to other tocolytic for failure.
Maintenance tocolysis: no.
Tocolysis for recurrent preterm labour: not reported.
Outcomes Maternal: nil.
Fetal/neonatal: fetal cerebral blood flow and IVH -primary outcomes. Birthweight and GA, RDS, NEC,
death
Notes Antenatal corticosteroid use: yes - all participants.
Sample size calculation: not reported.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Sawdy 2003
Methods Blinding of randomisation - yes.
Blinding of intervention - yes.
Complete follow up - yes.
Blinding of outcome measure - yes.
Participants 30 women 28-32 wks in preterm labour defined as contractions lasting >/= 30 secs every 5 mins and
cervical dilation >/= 2 cms
Exclusion criteria: multiple pregnancy, ruptured membranes, advance cervical dilatation. Contraindica-
tions to NSAID tocolytics: pregnancy complications, cervix >/= 4 cms, non reassuring fetal heat rate trace,
oligohydramnios, congenital abnormalities, placental praevia, thrombocytopenia, renal or liver dysfunc-
tion, platelet dysfunction, coagulation disorders, history of peptic ulcer
21Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Sawdy 2003 (Continued)
Interventions Intervention groups:
1. sulindac 200 mgs orally and a placebo suppository every 12 hrs;
2. nimesulide 200 mgs rectally and a placebo capsule orally every 12 hrs;
3. indomethacin -100 mg rectally and an placebo capsule orally every 12 hrs.
All study drugs were continued up to a maximum of 48 hrs.
All groups:
maintenance tocolysis: not reported.
Tocolysis for recurrent preterm labour: not reported.
Outcomes Amniotic fluid index, hourly fetal urine output, ductal pulsatile index, preterm birth, admission to NICU
Notes Antenatal corticosteroid use: yes - all participants.
Sample size calculation: yes - based on change in amniotic fluid index, hourly fetal urine output, ductal
pulsatile index
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Schorr 1998
Methods Blinding of randomisation - yes - sealed envelopes.
Blinding of intervention - no.
Complete follow up - yes.
Blinding of outcome measure - cannot tell.
Participants 88 women < 33 wks in preterm labour defined as contractions >/= 12 in 60 mins with cervix at least 2
cms dilated and 50% effaced. Singleton and twin pregnancies
Exclusion criteria: higher order multiples, ruptured membranes, fetal malformation, maternal disease,
chorioamnionitis, FGR, oligohydramnios
Interventions Intervention group:
ketorolac IM 60 mg load then 30 mg q6h for 24 hrs.
Control group:
magnesium sulphate IV 6 g bolus then 2-6 g/hr until uterine quiescence then slow tapering after 2 hrs
Both groups:
rescue tocolytic therapy:
no.
Maintenance tocolysis: yes - magnesium gluconate po until 37 weeks
Tocolysis for recurrent preterm labour: yes - as per study protocol
Outcomes Maternal:
adverse drug reaction, time to uterine quiescence, recurrent preterm labour, chorioamnionitis
Fetal/neonatal:
oligohydramnios, RDS, IVH, PDA, gestation at birth.
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Schorr 1998 (Continued)
Notes Antenatal corticosteroid use: yes - all participants.
Sample size calculation: yes - based on successful tocolysis at 4 hrs after treatment
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Stika 2002
Methods Blinding of randomisation - yes - sealed envelopes.
Blinding of intervention - yes.
Complete follow up - yes.
Blinding of outcome measure - yes.
Participants 24 women 24-34 wks in preterm labour defined as contractions with progressive dilatation or effacement
Exclusion criteria: multiple pregnancy, ruptured membranes, cervix >/= 4 cms, non reassuring fetal heat
rate trace, oligohydramnios, congenital abnormalities, placental praevia, thrombocytopenia, renal or liver
dysfunction, platelet dysfunction, coagulation disorders, history of peptic ulcer
Interventions Intervention group:
indomethacin suppository 100 mg then 50 mg po q6h for 48 hrs plus oral placebo
Control group:
celecoxib po 100 mg initially then 100 mg q12h for 48 hrs plus rectal and oral placebo
Both groups:
other tocolytic therapy: both study groups received MgSO4 concurrently with study medication for the
initial 2 hrs of treatment
Rescue tocolytic therapy: plan for MgSO4 however not required in study
Maintenance tocolysis: not reported.
Tocolysis for recurrent preterm labour: yes - MgSO4.
Outcomes Maternal:
adverse drug reaction, antepartum haemorrhage, chorioamnionitis, endometritis, caesarean section, olig-
uria, thromboxane production
Fetal/neonatal: oligohydramnios, ductal constriction, delivery within 48 hrs, Apgar score, admission to
NICU, RDS, MV, sepsis, NEC, IVH, other major cerebral abnormalities, birthweight and GA, duration
of MV and NICU stay
Notes Antenatal corticosteroid use: yes - all participants.
Sample size calculation: yes - based on ductal constriction of and change in AFI
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Zuckerman 1984
Methods Blinding of randomisation - cannot tell.
Blinding of intervention - yes.
Complete follow up - yes.
Blinding of outcome measure - yes.
Participants 36 women 25-35 wks in preterm labour defined as contractions 2 in 10 mins with cervical dilatation 1-2
cms or effacement
Exclusion criteria: multiple pregnancy, ruptured membranes, cervix > 4 cms dilated, chorioamnionitis,
antepartum haemorrhage, FGR, pre-eclampsia, diabetes
Interventions Intervention group:
indomethacin rectal suppository 100 mg then 25 mg po q4h for 24 hrs. Additional 100 mg suppository
if required. Total dose 200-300 mg in 24 hrs
Control group:
placebo.
Both groups:
rescue tocolytic therapy:
yes- ritodrine after 2 hrs if labour continued.
Maintenance tocolysis: not reported.
Tocolysis for recurrent preterm labour: not reported.
Outcomes Maternal:
drug reaction, caesarean section, progressive cervical dilatation at 2 hrs
Fetal/neonatal: preterm birth < 37 wks, birthweight and GA, pulmonary hypertension, RDS
Notes Antenatal corticosteroid use: not reported.
Sample size calculation: not reported.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
AFI: amniotic fluid index
CLD: chronic lung disease
FGR: fetal growth restriction
GA: gestational age
hrly: hourly
hrs: hours
IM: intramuscular
IV: intravenous
IVH: intraventricular haemorrhage
MgSO4: magnesium sulphate
min: minutes
MV: mechanical ventilation
NEC: necrotising enterocolitis
NICU: neonatal intensive care unit
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NRFS: non-reassuring fetal status
NSAIDs: nonsteroidal anti-inflammatory drugs
PDA: patent ductus arteriosus
po: orally
PPHN: persistent pulmonary hypertension of the newborn
PTL: preterm labour
q4h: every 4 hours
q6h: every 4 hours
q8h: every 8 hours
q12h: every 12 hours
RDS: respiratory distress syndrome
secs: seconds
TRH: thyrotropin-releasing hormone
wks: weeks
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abramov 2000 This trial compared different routes of administration of indomethacin for the treatment of women in preterm
labour: intravaginal versus intrarectal plus oral
Bivins 1993 A trial of maintenance therapy following successful tocolysis: indomethacin compared with terbutaline
Carlan 1992 Women were randomised following failed tocolysis to either indomethacin or sulindac
Carlan 1995 A trial of maintenance therapy following successful tocolysis:
sulindac compared with placebo.
Gamissans 1982 This trial assessed combination tocolytic therapy: ritodrine versus ritodrine plus indomethacin
Hallak 1992 This was not a tocolytic trial: women with a low-risk pregnancy were randomly assigned to either indomethacin
or terbutaline to assess the effects on fetal breathing and body movements
Humphrey 2001 A trial of maintenance therapy following successful tocolysis: sulindac compared with placebo
Katz 1983 This trial assessed combination tocolytic therapy: ritodrine versus ritodrine plus indomethacin
Mital 1992 Womenwere not in preterm labour at enrolment. This trial assessed the effects ofmefenamic acid in the prevention
of preterm labour for women at increased risk of preterm birth
Newton 1991 This trial assessed combination therapy for preterm labour: indomethacin, magnesium sulphate and antibiotics
versus magnesium sulphate alone
Rasanen 1995 Two non-selective COX inhibitors were compared for the treatment of women in preterm labour: indomethacin
versus sulindac
Rios-Anez 2001 This trial assessed combination tocolytic therapy: fenoterol alone versus fenoterol with indomethacin
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(Continued)
Spearing 1979 Quasi-random combination tocolytic trial comparing ethanol, ethanol plus indomethacin and salbutamol
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D A T A A N D A N A L Y S E S
Comparison 1. Any COX inhibitors compared with placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 3 106 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.25, 2.58]
2 Respiratory distress syndrome 3 106 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.40, 2.49]
3 Intraventricular haemorrhage
Grades III or IV
1 39 Risk Ratio (M-H, Fixed, 95% CI) 3.15 [0.14, 72.88]
4 Necrotising enterocolitis 2 70 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.21, 4.43]
5 Chronic neonatal lung disease 2 70 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.39, 3.94]
6 Preterm birth prior to 37 weeks 1 36 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.07, 0.62]
7 Interval from treatment to
delivery (subgrouped by
interval)
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
7.1 Delivery within 48 hours
of initiation of treatment
2 70 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.07, 0.51]
7.2 Delivery within 7 days of
initiation of treatment
2 70 Risk Ratio (M-H, Fixed, 95% CI) 0.44 [0.26, 0.74]
8 Gestation at birth 2 67 Mean Difference (IV, Fixed, 95% CI) 3.53 [1.13, 5.92]
9 Birthweight 2 67 Mean Difference (IV, Fixed, 95% CI) 716.34 [425.52,
1007.16]
10 Apgar score less than 7 at 5
minutes
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.05, 5.34]
11 Admission to neonatal intensive
care nursery
1 39 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.56, 1.15]
12 Persistent pulmonary
hypertension of the newborn
3 106 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
13 Patent ductus arteriosus 1 39 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.36, 5.46]
14 Neonatal sepsis 2 70 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.01, 7.15]
15 Maternal adverse drug reaction 3 101 Risk Ratio (M-H, Fixed, 95% CI) 1.58 [0.66, 3.78]
16 Postpartum haemorrhage 1 34 Risk Ratio (M-H, Fixed, 95% CI) 3.94 [0.95, 16.29]
17 Premature closure of the ductus
arteriosus
3 106 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18 Chorioamnionitis or
endometritis
2 64 Risk Ratio (M-H, Fixed, 95% CI) 1.94 [0.44, 8.60]
19 Caesarean section delivery 1 36 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.79]
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Comparison 2. Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 8 660 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.57, 3.74]
1.1 Any COX inhibitors
compared with any
betamimetic agent
4 237 Risk Ratio (M-H, Fixed, 95% CI) 0.99 [0.27, 3.57]
1.2 Any COX inhibitors
compared with magnesium
sulphate
4 423 Risk Ratio (M-H, Fixed, 95% CI) 2.31 [0.54, 9.90]
2 Respiratory distress syndrome 6 503 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.66, 1.76]
2.1 Any COX inhibitors
compared with any
betamimetic agent
2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.27, 8.34]
2.2 Any COX inhibitors
compared with magnesium
sulphate
4 423 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.62, 1.74]
3 Intraventricular haemorrhage
Grades III or IV
4 249 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.08, 4.40]
3.1 Any COX inhibitors
compared with any
betamimetic agent
1 20 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 Any COX inhibitors
compared with magnesium
sulphate
3 229 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.08, 4.40]
4 Intraventricular haemorrhage -
all grades
7 548 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.66, 2.11]
4.1 Any COX inhibitors
compared with any
betamimetic agent
3 125 Risk Ratio (M-H, Fixed, 95% CI) 5.34 [0.66, 43.10]
4.2 Any COX inhibitors
compared with magnesium
sulphate
4 423 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.49, 1.73]
5 Retinopathy of prematurity
Grades III or IV
1 20 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.1 Any COX inhibitors
compared with any
betamimetic agent
1 20 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Any COX inhibitors
compared with magnesium
sulphate
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Necrotising enterocolitis 4 298 Risk Ratio (M-H, Fixed, 95% CI) 3.82 [0.65, 22.51]
6.1 Any COX inhibitors
compared with any
betamimetic agent
2 80 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 70.83]
6.2 Any COX inhibitors
compared with magnesium
sulphate
2 218 Risk Ratio (M-H, Fixed, 95% CI) 4.24 [0.49, 36.45]
7 Preterm birth prior to 37 weeks 3 168 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.31, 0.94]
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7.1 Any COX inhibitors
compared with any
betamimetic agent
2 80 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.28, 0.99]
7.2 Any COX inhibitors
compared with magnesium
sulphate
1 88 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.17, 1.73]
8 Delivery within 48 hours of
initiation of treatment
4 415 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.34, 1.02]
8.1 Any COX inhibitors
compared with any
betamimetic agent
2 100 Risk Ratio (M-H, Fixed, 95% CI) 0.27 [0.08, 0.96]
8.2 Any COX inhibitors
compared with magnesium
sulphate
2 315 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.40, 1.40]
9 Delivery within 7 days of
initiation of treatment
2 146 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.52, 1.46]
9.1 Any COX inhibitors
compared with any
betamimetic agent
2 146 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.52, 1.46]
9.2 Any COX inhibitors
compared with magnesium
sulphate
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
10 Pregnancy prolongation (days) 1 101 Mean Difference (IV, Fixed, 95% CI) 0.20 [-4.66, 5.06]
10.1 Any COX inhibitors
compared with any
betamimetic
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
10.2 Any COX inhibitors
compared with magnesium
sulphate
1 101 Mean Difference (IV, Fixed, 95% CI) 0.20 [-4.66, 5.06]
11 Gestation at birth 5 411 Mean Difference (IV, Fixed, 95% CI) 0.59 [-0.20, 1.38]
11.1 Any COX inhibitors
compared with any
betamimetic
2 105 Mean Difference (IV, Fixed, 95% CI) 1.55 [-0.37, 3.48]
11.2 Any COX inhibitors
compared with magnesium
sulphate
3 306 Mean Difference (IV, Fixed, 95% CI) 0.40 [-0.47, 1.27]
12 Birthweight 5 424 Mean Difference (IV, Fixed, 95% CI) -56.77 [-195.90, 82.
36]
12.1 Any COX inhibitors
compared with any
betamimetic
2 105 Mean Difference (IV, Fixed, 95% CI) 199.40 [-176.85,
575.65]
12.2 Any COX inhibitors
compared with magnesium
sulphate
3 319 Mean Difference (IV, Fixed, 95% CI) -97.34 [-247.08, 52.
40]
13 Apgar score less than 7 at 5
minutes
2 254 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.21, 1.30]
13.1 Any COX inhibitors
compared with any
betamimetic agent
1 60 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 70.83]
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13.2 Any COX inhibitors
compared with magnesium
sulphate
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.16, 1.15]
14 Admission to neonatal intensive
care
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.48, 1.43]
14.1 Any COX inhibitors
compared with any
betamimetic agent
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14.2 Any COX inhibitors
compared with magnesium
sulphate
1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.48, 1.43]
15 Duration of neonatal intensive
care unit stay
1 194 Mean Difference (IV, Fixed, 95% CI) -1.80 [-7.09, 3.49]
15.1 Any COX inhibitors
compared with any
betamimetic
0 0 Mean Difference (IV, Fixed, 95% CI) Not estimable
15.2 Any COX inhibitors
compared with magnesium
sulphate
1 194 Mean Difference (IV, Fixed, 95% CI) -1.80 [-7.09, 3.49]
16 Neonatal mechanical
ventilation
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.47, 4.78]
16.1 Any COX inhibitors
compared with any
betamimetic agent
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.5 [0.47, 4.78]
16.2 Any COX inhibitors
compared with magnesium
sulphate
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17 Persistent pulmonary
hypertension of the newborn
5 490 Risk Ratio (M-H, Fixed, 95% CI) 2.85 [0.56, 14.38]
17.1 Any COX inhibitors
compared with any
betamimetic agent
3 177 Risk Ratio (M-H, Fixed, 95% CI) 5.65 [0.31, 103.46]
17.2 Any COX inhibitors
compared with magnesium
sulphate
3 313 Risk Ratio (M-H, Fixed, 95% CI) 1.78 [0.23, 13.44]
18 Neonatal renal failure 1 20 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18.1 Any COX inhibitors
compared with any
betamimetic agent
1 20 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
18.2 Any COX inhibitors
compared with magnesium
sulphate
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
19 Patent ductus arteriosus 4 213 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.24, 2.51]
19.1 Any COX inhibitors
compared with any
betamimetic agent
3 125 Risk Ratio (M-H, Fixed, 95% CI) 1.66 [0.36, 7.66]
19.2 Any COX inhibitors
compared with magnesium
sulphate
1 88 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.01, 2.57]
20 Neonatal sepsis 2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
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20.1 Any COX inhibitors
compared with any
betamimetic agent
2 80 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 15.26]
20.2 Any COX inhibitors
compared with magnesium
sulphate
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
21 Maternal adverse drug reaction 7 629 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.15, 0.33]
21.1 Any COX inhibitors
compared with any
betamimetic agent
4 226 Risk Ratio (M-H, Fixed, 95% CI) 0.10 [0.05, 0.20]
21.2 Any COX inhibitors
compared with magnesium
sulphate
3 403 Risk Ratio (M-H, Fixed, 95% CI) 0.41 [0.26, 0.66]
22 Maternal adverse drug reaction
requiring cessation of treatment
5 355 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.02, 0.29]
22.1 Any COX inhibitors
compared with any
betamimetic agent
3 166 Risk Ratio (M-H, Fixed, 95% CI) 0.07 [0.01, 0.37]
22.2 Any COX inhibitors
compared with magnesium
sulphate
2 189 Risk Ratio (M-H, Fixed, 95% CI) 0.06 [0.00, 1.05]
23 Oligohydramnios 3 295 Risk Ratio (M-H, Fixed, 95% CI) 2.53 [0.76, 8.46]
23.1 Any COX inhibitors
compared with any
betamimetic agent
1 106 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.55, 7.87]
23.2 Any COX inhibitors
compared with magnesium
sulphate
2 189 Risk Ratio (M-H, Fixed, 95% CI) 5.3 [0.26, 107.70]
24 Premature closure of the ductus
arteriosus
4 337 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [0.13, 73.39]
24.1 Any COX inhibitors
compared with any
betamimetic agent
2 132 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
24.2 Any COX inhibitors
compared with magnesium
sulphate
2 205 Risk Ratio (M-H, Fixed, 95% CI) 3.05 [0.13, 73.39]
25 Chorioamnionitis or
endometritis
1 88 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
25.1 Any COX inhibitors
compared with any
betamimetic agent
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
25.2 Any COX inhibitors
compared with magnesium
sulphate
1 88 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
26 Caesarean section delivery 1 194 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.70, 2.13]
26.1 Any COX inhibitors
compared with any
betamimetic agent
0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
26.2 Any COX inhibitors
compared with magnesium
sulphate
1 194 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.70, 2.13]
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Comparison 3. Indomethacin compared with any COX-2 inhibitors
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Perinatal mortality 2 54 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2 Respiratory distress syndrome 1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.21]
3 Intraventricular haemorrhage
Grades III or IV
1 24 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
4 Intraventricular haemorrhage -
all grades
1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.05, 4.81]
5 Necrotising enterocolitis 1 24 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Interval from treatment to
delivery (subgrouped by
interval)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Delivery within or at 48
hours of initiation of treatment
1 24 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 Delivery within 7 days of
initiation of treatment
1 24 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.06]
7 Gestation at birth 1 24 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Birthweight 1 24 Mean Difference (IV, Fixed, 95% CI) 27.0 [-549.58, 603.
58]
9 Apgar score less than 7 at 5
minutes
1 24 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.13, 67.06]
10 Admission to neonatal intensive
care nursery
2 54 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.34, 2.91]
11 Neonatal mechanical
ventilation
1 24 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.07, 14.21]
12 Neonatal sepsis 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.45]
13 Maternal adverse drug reaction 2 54 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
14 Antepartum haemorrhage 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 7.45]
15 Oligohydramnios 1 24 Risk Ratio (M-H, Fixed, 95% CI) 4.0 [0.52, 30.76]
16 Premature closure of the ductus
arteriosus
2 54 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
17 Chorioamnionitis or
endometritis
1 24 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.21, 19.23]
18 Caesarean section delivery 1 24 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.13, 3.30]
19 Preterm birth before 37 weeks 2 54 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.31, 3.19]
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Analysis 1.1. Comparison 1 Any COX inhibitors compared with placebo, Outcome 1 Perinatal mortality.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 1 Perinatal mortality
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 2/16 3/15 55.5 % 0.63 [ 0.12, 3.24 ]
Panter 1999 1/19 0/20 8.7 % 3.15 [ 0.14, 72.88 ]
Zuckerman 1984 1/18 2/18 35.8 % 0.50 [ 0.05, 5.04 ]
Total (95% CI) 53 53 100.0 % 0.80 [ 0.25, 2.58 ]
Total events: 4 (Any COX inhibitor), 5 (Placebo)
Heterogeneity: Chi2 = 0.98, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
0.01 0.1 1 10 100
Favours COX inhibit Favours placebo
Analysis 1.2. Comparison 1 Any COX inhibitors compared with placebo, Outcome 2 Respiratory distress
syndrome.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 2 Respiratory distress syndrome
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 3/16 2/15 25.8 % 1.41 [ 0.27, 7.28 ]
Panter 1999 4/19 2/20 24.3 % 2.11 [ 0.43, 10.19 ]
Zuckerman 1984 1/18 4/18 49.9 % 0.25 [ 0.03, 2.02 ]
Total (95% CI) 53 53 100.0 % 1.00 [ 0.40, 2.49 ]
Total events: 8 (Any COX inhibitor), 8 (Placebo)
Heterogeneity: Chi2 = 2.71, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.00 (P = 1.0)
0.01 0.1 1 10 100
Favours COX inhibit Favours placebo
33Cyclo-oxygenase (COX) inhibitors for treating preterm labour (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.3. Comparison 1 Any COX inhibitors compared with placebo, Outcome 3 Intraventricular
haemorrhage Grades III or IV.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 3 Intraventricular haemorrhage Grades III or IV
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Panter 1999 1/19 0/20 100.0 % 3.15 [ 0.14, 72.88 ]
Total (95% CI) 19 20 100.0 % 3.15 [ 0.14, 72.88 ]
Total events: 1 (Any COX inhibitor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
0.01 0.1 1 10 100
Favours COX inhibit Favours placebo
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Analysis 1.4. Comparison 1 Any COX inhibitors compared with placebo, Outcome 4 Necrotising
enterocolitis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 4 Necrotising enterocolitis
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 2/16 2/15 67.9 % 0.94 [ 0.15, 5.84 ]
Panter 1999 1/19 1/20 32.1 % 1.05 [ 0.07, 15.66 ]
Total (95% CI) 35 35 100.0 % 0.97 [ 0.21, 4.43 ]
Total events: 3 (Any COX inhibitor), 3 (Placebo)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
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Analysis 1.5. Comparison 1 Any COX inhibitors compared with placebo, Outcome 5 Chronic neonatal lung
disease.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 5 Chronic neonatal lung disease
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 0/16 2/15 56.9 % 0.19 [ 0.01, 3.63 ]
Panter 1999 5/19 2/20 43.1 % 2.63 [ 0.58, 11.97 ]
Total (95% CI) 35 35 100.0 % 1.24 [ 0.39, 3.94 ]
Total events: 5 (Any COX inhibitor), 4 (Placebo)
Heterogeneity: Chi2 = 2.51, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 1.6. Comparison 1 Any COX inhibitors compared with placebo, Outcome 6 Preterm birth prior to
37 weeks.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 6 Preterm birth prior to 37 weeks
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zuckerman 1984 3/18 14/18 100.0 % 0.21 [ 0.07, 0.62 ]
Total (95% CI) 18 18 100.0 % 0.21 [ 0.07, 0.62 ]
Total events: 3 (Any COX inhibitor), 14 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.84 (P = 0.0045)
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Analysis 1.7. Comparison 1 Any COX inhibitors compared with placebo, Outcome 7 Interval from
treatment to delivery (subgrouped by interval).
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 7 Interval from treatment to delivery (subgrouped by interval)
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Delivery within 48 hours of initiation of treatment
Panter 1999 3/16 8/18 35.0 % 0.42 [ 0.13, 1.32 ]
Zuckerman 1984 1/18 14/18 65.0 % 0.07 [ 0.01, 0.49 ]
Subtotal (95% CI) 34 36 100.0 % 0.19 [ 0.07, 0.51 ]
Total events: 4 (Any COX inhibitor), 22 (Placebo)
Heterogeneity: Chi2 = 2.81, df = 1 (P = 0.09); I2 =64%
Test for overall effect: Z = 3.35 (P = 0.00082)
2 Delivery within 7 days of initiation of treatment
Panter 1999 8/16 12/18 43.0 % 0.75 [ 0.42, 1.35 ]
Zuckerman 1984 3/18 15/18 57.0 % 0.20 [ 0.07, 0.57 ]
Subtotal (95% CI) 34 36 100.0 % 0.44 [ 0.26, 0.74 ]
Total events: 11 (Any COX inhibitor), 27 (Placebo)
Heterogeneity: Chi2 = 5.36, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 3.10 (P = 0.0020)
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Analysis 1.8. Comparison 1 Any COX inhibitors compared with placebo, Outcome 8 Gestation at birth.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 8 Gestation at birth
Study or subgroup Any COX inhibitor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Niebyl 1980 16 35.2 (4.4) 15 33 (4.7) 55.8 % 2.20 [ -1.01, 5.41 ]
Zuckerman 1984 18 36.4 (7.2) 18 31.2 (3) 44.2 % 5.20 [ 1.60, 8.80 ]
Total (95% CI) 34 33 100.0 % 3.53 [ 1.13, 5.92 ]
Heterogeneity: Chi2 = 1.48, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 2.88 (P = 0.0039)
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Any COX inhibitors compared with placebo, Outcome 9 Birthweight.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 9 Birthweight
Study or subgroup Any COX inhibitor Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Niebyl 1980 16 2358 (848.2) 15 1929 (852.1) 23.6 % 429.00 [ -169.90, 1027.90 ]
Zuckerman 1984 18 2833 (496.3) 18 2028 (521.8) 76.4 % 805.00 [ 472.32, 1137.68 ]
Total (95% CI) 34 33 100.0 % 716.34 [ 425.52, 1007.16 ]
Heterogeneity: Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 4.83 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.10. Comparison 1 Any COX inhibitors compared with placebo, Outcome 10 Apgar score less
than 7 at 5 minutes.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 10 Apgar score less than 7 at 5 minutes
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Panter 1999 1/19 2/20 100.0 % 0.53 [ 0.05, 5.34 ]
Total (95% CI) 19 20 100.0 % 0.53 [ 0.05, 5.34 ]
Total events: 1 (Any COX inhibitor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
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Analysis 1.11. Comparison 1 Any COX inhibitors compared with placebo, Outcome 11 Admission to
neonatal intensive care nursery.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 11 Admission to neonatal intensive care nursery
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Panter 1999 13/19 17/20 100.0 % 0.80 [ 0.56, 1.15 ]
Total (95% CI) 19 20 100.0 % 0.80 [ 0.56, 1.15 ]
Total events: 13 (Any COX inhibitor), 17 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
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Analysis 1.12. Comparison 1 Any COX inhibitors compared with placebo, Outcome 12 Persistent
pulmonary hypertension of the newborn.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 12 Persistent pulmonary hypertension of the newborn
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 0/16 0/15 Not estimable
Panter 1999 0/19 0/20 Not estimable
Zuckerman 1984 0/18 0/18 Not estimable
Total (95% CI) 53 53 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.13. Comparison 1 Any COX inhibitors compared with placebo, Outcome 13 Patent ductus
arteriosus.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 13 Patent ductus arteriosus
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Panter 1999 4/19 3/20 100.0 % 1.40 [ 0.36, 5.46 ]
Total (95% CI) 19 20 100.0 % 1.40 [ 0.36, 5.46 ]
Total events: 4 (Any COX inhibitor), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.49 (P = 0.62)
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Analysis 1.14. Comparison 1 Any COX inhibitors compared with placebo, Outcome 14 Neonatal sepsis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 14 Neonatal sepsis
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 0/16 1/15 100.0 % 0.31 [ 0.01, 7.15 ]
Panter 1999 0/19 0/20 Not estimable
Total (95% CI) 35 35 100.0 % 0.31 [ 0.01, 7.15 ]
Total events: 0 (Any COX inhibitor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
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Analysis 1.15. Comparison 1 Any COX inhibitors compared with placebo, Outcome 15 Maternal adverse
drug reaction.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 15 Maternal adverse drug reaction
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 1/16 0/15 8.3 % 2.82 [ 0.12, 64.39 ]
Panter 1999 6/16 5/18 75.6 % 1.35 [ 0.51, 3.59 ]
Zuckerman 1984 2/18 1/18 16.1 % 2.00 [ 0.20, 20.15 ]
Total (95% CI) 50 51 100.0 % 1.58 [ 0.66, 3.78 ]
Total events: 9 (Any COX inhibitor), 6 (Placebo)
Heterogeneity: Chi2 = 0.27, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
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Analysis 1.16. Comparison 1 Any COX inhibitors compared with placebo, Outcome 16 Postpartum
haemorrhage.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 16 Postpartum haemorrhage
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Panter 1999 7/16 2/18 100.0 % 3.94 [ 0.95, 16.29 ]
Total (95% CI) 16 18 100.0 % 3.94 [ 0.95, 16.29 ]
Total events: 7 (Any COX inhibitor), 2 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.89 (P = 0.059)
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Analysis 1.17. Comparison 1 Any COX inhibitors compared with placebo, Outcome 17 Premature closure
of the ductus arteriosus.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 17 Premature closure of the ductus arteriosus
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 0/16 0/15 Not estimable
Panter 1999 0/19 0/20 Not estimable
Zuckerman 1984 0/18 0/18 Not estimable
Total (95% CI) 53 53 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.18. Comparison 1 Any COX inhibitors compared with placebo, Outcome 18 Chorioamnionitis or
endometritis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 18 Chorioamnionitis or endometritis
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Niebyl 1980 2/15 0/15 21.0 % 5.00 [ 0.26, 96.13 ]
Panter 1999 2/16 2/18 79.0 % 1.13 [ 0.18, 7.09 ]
Total (95% CI) 31 33 100.0 % 1.94 [ 0.44, 8.60 ]
Total events: 4 (Any COX inhibitor), 2 (Placebo)
Heterogeneity: Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.87 (P = 0.38)
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Analysis 1.19. Comparison 1 Any COX inhibitors compared with placebo, Outcome 19 Caesarean section
delivery.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 1 Any COX inhibitors compared with placebo
Outcome: 19 Caesarean section delivery
Study or subgroup Any COX inhibitor Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Zuckerman 1984 1/18 1/18 100.0 % 1.00 [ 0.07, 14.79 ]
Total (95% CI) 18 18 100.0 % 1.00 [ 0.07, 14.79 ]
Total events: 1 (Any COX inhibitor), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 2.1. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 1 Perinatal mortality.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 1 Perinatal mortality
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 1/25 1/20 15.9 % 0.80 [ 0.05, 12.01 ]
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 1/30 0/30 7.2 % 3.00 [ 0.13, 70.83 ]
Morales 1989 2/54 3/58 41.5 % 0.72 [ 0.12, 4.12 ]
Subtotal (95% CI) 119 118 64.6 % 0.99 [ 0.27, 3.57 ]
Total events: 4 (Any COX inhibitor), 4 (Other tocolytic)
Heterogeneity: Chi2 = 0.63, df = 2 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 3/92 0/102 6.8 % 7.75 [ 0.41, 148.11 ]
Morales 1993 1/58 1/59 14.2 % 1.02 [ 0.07, 15.88 ]
Parilla 1997 1/12 1/12 14.3 % 1.00 [ 0.07, 14.21 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 207 216 35.4 % 2.31 [ 0.54, 9.90 ]
Total events: 5 (Any COX inhibitor), 2 (Other tocolytic)
Heterogeneity: Chi2 = 1.37, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.12 (P = 0.26)
Total (95% CI) 326 334 100.0 % 1.46 [ 0.57, 3.74 ]
Total events: 9 (Any COX inhibitor), 6 (Other tocolytic)
Heterogeneity: Chi2 = 2.40, df = 5 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.43)
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Analysis 2.2. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 2 Respiratory distress syndrome.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 2 Respiratory distress syndrome
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 3/30 2/30 7.7 % 1.50 [ 0.27, 8.34 ]
Subtotal (95% CI) 40 40 7.7 % 1.50 [ 0.27, 8.34 ]
Total events: 3 (Any COX inhibitor), 2 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 18/92 19/102 69.4 % 1.05 [ 0.59, 1.88 ]
Morales 1993 5/58 5/59 19.1 % 1.02 [ 0.31, 3.33 ]
Parilla 1997 1/12 1/12 3.8 % 1.00 [ 0.07, 14.21 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 207 216 92.3 % 1.04 [ 0.62, 1.74 ]
Total events: 24 (Any COX inhibitor), 25 (Other tocolytic)
Heterogeneity: Chi2 = 0.00, df = 2 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
Total (95% CI) 247 256 100.0 % 1.08 [ 0.66, 1.76 ]
Total events: 27 (Any COX inhibitor), 27 (Other tocolytic)
Heterogeneity: Chi2 = 0.16, df = 3 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
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Analysis 2.3. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 3 Intraventricular haemorrhage Grades III or IV.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 3 Intraventricular haemorrhage Grades III or IV
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
Morales 1993 1/58 1/59 39.8 % 1.02 [ 0.07, 15.88 ]
Parilla 1997 0/12 1/12 60.2 % 0.33 [ 0.01, 7.45 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 115 114 100.0 % 0.61 [ 0.08, 4.40 ]
Total events: 1 (Any COX inhibitor), 2 (Other tocolytic)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Total (95% CI) 125 124 100.0 % 0.61 [ 0.08, 4.40 ]
Total events: 1 (Any COX inhibitor), 2 (Other tocolytic)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 2.4. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 4 Intraventricular haemorrhage - all grades.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 4 Intraventricular haemorrhage - all grades
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 3/25 0/20 3.0 % 5.65 [ 0.31, 103.46 ]
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 2/30 0/30 2.8 % 5.00 [ 0.25, 99.95 ]
Subtotal (95% CI) 65 60 5.8 % 5.34 [ 0.66, 43.10 ]
Total events: 5 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 6/92 7/102 36.5 % 0.95 [ 0.33, 2.72 ]
Morales 1993 4/58 4/59 21.8 % 1.02 [ 0.27, 3.88 ]
Parilla 1997 4/12 6/12 33.0 % 0.67 [ 0.25, 1.78 ]
Schorr 1998 1/45 0/43 2.8 % 2.87 [ 0.12, 68.58 ]
Subtotal (95% CI) 207 216 94.2 % 0.92 [ 0.49, 1.73 ]
Total events: 15 (Any COX inhibitor), 17 (Other tocolytic)
Heterogeneity: Chi2 = 0.94, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
Total (95% CI) 272 276 100.0 % 1.18 [ 0.66, 2.11 ]
Total events: 20 (Any COX inhibitor), 17 (Other tocolytic)
Heterogeneity: Chi2 = 3.82, df = 5 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
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Analysis 2.5. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 5 Retinopathy of prematurity Grades III or IV.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 5 Retinopathy of prematurity Grades III or IV
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 10 10 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.6. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 6 Necrotising enterocolitis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 6 Necrotising enterocolitis
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 1/30 0/30 33.9 % 3.00 [ 0.13, 70.83 ]
Subtotal (95% CI) 40 40 33.9 % 3.00 [ 0.13, 70.83 ]
Total events: 1 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 2/92 0/102 32.2 % 5.54 [ 0.27, 113.86 ]
Parilla 1997 1/12 0/12 33.9 % 3.00 [ 0.13, 67.06 ]
Subtotal (95% CI) 104 114 66.1 % 4.24 [ 0.49, 36.45 ]
Total events: 3 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
Total (95% CI) 144 154 100.0 % 3.82 [ 0.65, 22.51 ]
Total events: 4 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.48 (P = 0.14)
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Analysis 2.7. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 7 Preterm birth prior to 37 weeks.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 7 Preterm birth prior to 37 weeks
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 9/30 17/30 70.4 % 0.53 [ 0.28, 0.99 ]
Subtotal (95% CI) 40 40 70.4 % 0.53 [ 0.28, 0.99 ]
Total events: 9 (Any COX inhibitor), 17 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.048)
2 Any COX inhibitors compared with magnesium sulphate
Schorr 1998 4/45 7/43 29.6 % 0.55 [ 0.17, 1.73 ]
Subtotal (95% CI) 45 43 29.6 % 0.55 [ 0.17, 1.73 ]
Total events: 4 (Any COX inhibitor), 7 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 85 83 100.0 % 0.53 [ 0.31, 0.94 ]
Total events: 13 (Any COX inhibitor), 24 (Other tocolytic)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
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Analysis 2.8. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 8 Delivery within 48 hours of initiation of treatment.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 8 Delivery within 48 hours of initiation of treatment
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 2/22 3/18 10.7 % 0.55 [ 0.10, 2.92 ]
Kurki 1991 1/30 7/30 22.7 % 0.14 [ 0.02, 1.09 ]
Subtotal (95% CI) 52 48 33.4 % 0.27 [ 0.08, 0.96 ]
Total events: 3 (Any COX inhibitor), 10 (Other tocolytic)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 2.03 (P = 0.042)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 10/105 13/109 41.4 % 0.80 [ 0.37, 1.74 ]
Morales 1993 5/49 8/52 25.2 % 0.66 [ 0.23, 1.89 ]
Subtotal (95% CI) 154 161 66.6 % 0.75 [ 0.40, 1.40 ]
Total events: 15 (Any COX inhibitor), 21 (Other tocolytic)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
Total (95% CI) 206 209 100.0 % 0.59 [ 0.34, 1.02 ]
Total events: 18 (Any COX inhibitor), 31 (Other tocolytic)
Heterogeneity: Chi2 = 2.51, df = 3 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.058)
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Analysis 2.9. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 9 Delivery within 7 days of initiation of treatment.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 9 Delivery within 7 days of initiation of treatment
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 7/22 6/18 29.6 % 0.95 [ 0.39, 2.34 ]
Morales 1989 13/52 16/54 70.4 % 0.84 [ 0.45, 1.58 ]
Subtotal (95% CI) 74 72 100.0 % 0.88 [ 0.52, 1.46 ]
Total events: 20 (Any COX inhibitor), 22 (Other tocolytic)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
2 Any COX inhibitors compared with magnesium sulphate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 74 72 100.0 % 0.88 [ 0.52, 1.46 ]
Total events: 20 (Any COX inhibitor), 22 (Other tocolytic)
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.61)
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Analysis 2.10. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 10 Pregnancy prolongation (days).
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 10 Pregnancy prolongation (days)
Study or subgroup Any COX inhibitor Other tocolytic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
Morales 1993 49 22.9 (11.5) 52 22.7 (13.4) 100.0 % 0.20 [ -4.66, 5.06 ]
Subtotal (95% CI) 49 52 100.0 % 0.20 [ -4.66, 5.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Total (95% CI) 49 52 100.0 % 0.20 [ -4.66, 5.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
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Analysis 2.11. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 11 Gestation at birth.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 11 Gestation at birth
Study or subgroup Any COX inhibitor Other tocolytic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic
Besinger 1991 25 35.5 (5.7) 20 33.8 (7.1) 4.3 % 1.70 [ -2.13, 5.53 ]
Kurki 1991 30 36.7 (4.4) 30 35.2 (4.4) 12.6 % 1.50 [ -0.73, 3.73 ]
Subtotal (95% CI) 55 50 16.9 % 1.55 [ -0.37, 3.48 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 92 35.3 (3.4) 102 34.7 (4.2) 54.5 % 0.60 [ -0.47, 1.67 ]
Parilla 1997 12 30.8 (3.8) 12 31.1 (4.3) 5.9 % -0.30 [ -3.55, 2.95 ]
Schorr 1998 45 34.9 (3.6) 43 34.8 (4.3) 22.7 % 0.10 [ -1.56, 1.76 ]
Subtotal (95% CI) 149 157 83.1 % 0.40 [ -0.47, 1.27 ]
Heterogeneity: Chi2 = 0.44, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI) 204 207 100.0 % 0.59 [ -0.20, 1.38 ]
Heterogeneity: Chi2 = 1.59, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Test for subgroup differences: Chi2 = 1.14, df = 1 (P = 0.29), I2 =12%
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Analysis 2.12. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 12 Birthweight.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 12 Birthweight
Study or subgroup Any COX inhibitor Other tocolytic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic
Besinger 1991 25 2090 (1202) 20 2189 (1104) 4.2 % -99.00 [ -774.36, 576.36 ]
Kurki 1991 30 2892 (952.5) 30 2558.3 (834.2) 9.4 % 333.70 [ -119.38, 786.78 ]
Subtotal (95% CI) 55 50 13.7 % 199.40 [ -176.85, 575.65 ]
Heterogeneity: Chi2 = 1.09, df = 1 (P = 0.30); I2 =8%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 92 2585 (778) 102 2530 (902) 34.6 % 55.00 [ -181.46, 291.46 ]
Morales 1993 49 1808 (390) 52 2030 (627) 47.3 % -222.00 [ -424.40, -19.60 ]
Parilla 1997 12 1622 (589) 12 1581 (1005) 4.5 % 41.00 [ -618.08, 700.08 ]
Subtotal (95% CI) 153 166 86.3 % -97.34 [ -247.08, 52.40 ]
Heterogeneity: Chi2 = 3.22, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 1.27 (P = 0.20)
Total (95% CI) 208 216 100.0 % -56.77 [ -195.90, 82.36 ]
Heterogeneity: Chi2 = 6.37, df = 4 (P = 0.17); I2 =37%
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Chi2 = 2.06, df = 1 (P = 0.15), I2 =52%
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Analysis 2.13. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 13 Apgar score less than 7 at 5 minutes.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 13 Apgar score less than 7 at 5 minutes
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kurki 1991 1/30 0/30 3.9 % 3.00 [ 0.13, 70.83 ]
Subtotal (95% CI) 30 30 3.9 % 3.00 [ 0.13, 70.83 ]
Total events: 1 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 5/92 13/102 96.1 % 0.43 [ 0.16, 1.15 ]
Subtotal (95% CI) 92 102 96.1 % 0.43 [ 0.16, 1.15 ]
Total events: 5 (Any COX inhibitor), 13 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
Total (95% CI) 122 132 100.0 % 0.53 [ 0.21, 1.30 ]
Total events: 6 (Any COX inhibitor), 13 (Other tocolytic)
Heterogeneity: Chi2 = 1.34, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.39 (P = 0.17)
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Analysis 2.14. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 14 Admission to neonatal intensive care.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 14 Admission to neonatal intensive care
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 18/92 24/102 100.0 % 0.83 [ 0.48, 1.43 ]
Subtotal (95% CI) 92 102 100.0 % 0.83 [ 0.48, 1.43 ]
Total events: 18 (Any COX inhibitor), 24 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Total (95% CI) 92 102 100.0 % 0.83 [ 0.48, 1.43 ]
Total events: 18 (Any COX inhibitor), 24 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 2.15. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 15 Duration of neonatal intensive care unit stay.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 15 Duration of neonatal intensive care unit stay
Study or subgroup Any COX inhibitor Other tocolytic
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 92 6.7 (17.1) 102 8.5 (20.5) 100.0 % -1.80 [ -7.09, 3.49 ]
Subtotal (95% CI) 92 102 100.0 % -1.80 [ -7.09, 3.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
Total (95% CI) 92 102 100.0 % -1.80 [ -7.09, 3.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.51)
Test for subgroup differences: Not applicable
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Analysis 2.16. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 16 Neonatal mechanical ventilation.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 16 Neonatal mechanical ventilation
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kurki 1991 6/30 4/30 100.0 % 1.50 [ 0.47, 4.78 ]
Subtotal (95% CI) 30 30 100.0 % 1.50 [ 0.47, 4.78 ]
Total events: 6 (Any COX inhibitor), 4 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
2 Any COX inhibitors compared with magnesium sulphate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 30 30 100.0 % 1.50 [ 0.47, 4.78 ]
Total events: 6 (Any COX inhibitor), 4 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.17. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 17 Persistent pulmonary hypertension of the newborn.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 17 Persistent pulmonary hypertension of the newborn
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 3/25 0/20 27.7 % 5.65 [ 0.31, 103.46 ]
Kramer 1999 0/10 0/10 Not estimable
Morales 1989 0/54 0/58 Not estimable
Subtotal (95% CI) 89 88 27.7 % 5.65 [ 0.31, 103.46 ]
Total events: 3 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
2 Any COX inhibitors compared with magnesium sulphate
Besinger 1991 0/1 0/1 Not estimable
McWhorter 2004 1/92 1/102 47.5 % 1.11 [ 0.07, 17.47 ]
Morales 1993 1/58 0/59 24.8 % 3.05 [ 0.13, 73.39 ]
Subtotal (95% CI) 151 162 72.3 % 1.78 [ 0.23, 13.44 ]
Total events: 2 (Any COX inhibitor), 1 (Other tocolytic)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Total (95% CI) 240 250 100.0 % 2.85 [ 0.56, 14.38 ]
Total events: 5 (Any COX inhibitor), 1 (Other tocolytic)
Heterogeneity: Chi2 = 0.67, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
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Analysis 2.18. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 18 Neonatal renal failure.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 18 Neonatal renal failure
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Subtotal (95% CI) 10 10 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 10 10 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.19. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 19 Patent ductus arteriosus.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 19 Patent ductus arteriosus
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 2/25 0/20 9.0 % 4.04 [ 0.20, 79.62 ]
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 2/30 2/30 32.6 % 1.00 [ 0.15, 6.64 ]
Subtotal (95% CI) 65 60 41.6 % 1.66 [ 0.36, 7.66 ]
Total events: 4 (Any COX inhibitor), 2 (Other tocolytic)
Heterogeneity: Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
2 Any COX inhibitors compared with magnesium sulphate
Schorr 1998 0/45 3/43 58.4 % 0.14 [ 0.01, 2.57 ]
Subtotal (95% CI) 45 43 58.4 % 0.14 [ 0.01, 2.57 ]
Total events: 0 (Any COX inhibitor), 3 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
Total (95% CI) 110 103 100.0 % 0.77 [ 0.24, 2.51 ]
Total events: 4 (Any COX inhibitor), 5 (Other tocolytic)
Heterogeneity: Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.43 (P = 0.66)
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Analysis 2.20. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 20 Neonatal sepsis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 20 Neonatal sepsis
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Kurki 1991 1/30 1/30 100.0 % 1.00 [ 0.07, 15.26 ]
Subtotal (95% CI) 40 40 100.0 % 1.00 [ 0.07, 15.26 ]
Total events: 1 (Any COX inhibitor), 1 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Any COX inhibitors compared with magnesium sulphate
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 40 40 100.0 % 1.00 [ 0.07, 15.26 ]
Total events: 1 (Any COX inhibitor), 1 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 2.21. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 21 Maternal adverse drug reaction.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 21 Maternal adverse drug reaction
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 0/22 6/18 5.9 % 0.06 [ 0.00, 1.06 ]
Kramer 1999 0/10 5/10 4.5 % 0.09 [ 0.01, 1.45 ]
Kurki 1991 6/30 25/30 20.6 % 0.24 [ 0.12, 0.50 ]
Morales 1989 0/52 36/54 29.5 % 0.01 [ 0.00, 0.23 ]
Subtotal (95% CI) 114 112 60.4 % 0.10 [ 0.05, 0.20 ]
Total events: 6 (Any COX inhibitor), 72 (Other tocolytic)
Heterogeneity: Chi2 = 7.33, df = 3 (P = 0.06); I2 =59%
Test for overall effect: Z = 6.42 (P < 0.00001)
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 17/109 32/105 26.8 % 0.51 [ 0.30, 0.86 ]
Morales 1993 3/49 16/52 12.8 % 0.20 [ 0.06, 0.64 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 203 200 39.6 % 0.41 [ 0.26, 0.66 ]
Total events: 20 (Any COX inhibitor), 48 (Other tocolytic)
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =54%
Test for overall effect: Z = 3.67 (P = 0.00024)
Total (95% CI) 317 312 100.0 % 0.22 [ 0.15, 0.33 ]
Total events: 26 (Any COX inhibitor), 120 (Other tocolytic)
Heterogeneity: Chi2 = 14.63, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 7.69 (P < 0.00001)
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Analysis 2.22. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 22 Maternal adverse drug reaction requiring cessation of treatment.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 22 Maternal adverse drug reaction requiring cessation of treatment
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Besinger 1991 0/22 1/18 5.7 % 0.28 [ 0.01, 6.38 ]
Kramer 1999 0/10 5/10 19.2 % 0.09 [ 0.01, 1.45 ]
Morales 1989 0/52 13/54 46.3 % 0.04 [ 0.00, 0.63 ]
Subtotal (95% CI) 84 82 71.2 % 0.07 [ 0.01, 0.37 ]
Total events: 0 (Any COX inhibitor), 19 (Other tocolytic)
Heterogeneity: Chi2 = 0.92, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0018)
2 Any COX inhibitors compared with magnesium sulphate
Morales 1993 0/49 8/52 28.8 % 0.06 [ 0.00, 1.05 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 94 95 28.8 % 0.06 [ 0.00, 1.05 ]
Total events: 0 (Any COX inhibitor), 8 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.054)
Total (95% CI) 178 177 100.0 % 0.07 [ 0.02, 0.29 ]
Total events: 0 (Any COX inhibitor), 27 (Other tocolytic)
Heterogeneity: Chi2 = 0.96, df = 3 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.67 (P = 0.00024)
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Analysis 2.23. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 23 Oligohydramnios.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 23 Oligohydramnios
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Morales 1989 6/52 3/54 85.8 % 2.08 [ 0.55, 7.87 ]
Subtotal (95% CI) 52 54 85.8 % 2.08 [ 0.55, 7.87 ]
Total events: 6 (Any COX inhibitor), 3 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
2 Any COX inhibitors compared with magnesium sulphate
Morales 1993 2/49 0/52 14.2 % 5.30 [ 0.26, 107.70 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 94 95 14.2 % 5.30 [ 0.26, 107.70 ]
Total events: 2 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
Total (95% CI) 146 149 100.0 % 2.53 [ 0.76, 8.46 ]
Total events: 8 (Any COX inhibitor), 3 (Other tocolytic)
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 2.24. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 24 Premature closure of the ductus arteriosus.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 24 Premature closure of the ductus arteriosus
Study or subgroup Any COX inhibitor Other tocolytiic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Kramer 1999 0/10 0/10 Not estimable
Morales 1989 0/54 0/58 Not estimable
Subtotal (95% CI) 64 68 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytiic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
Morales 1993 1/58 0/59 100.0 % 3.05 [ 0.13, 73.39 ]
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 103 102 100.0 % 3.05 [ 0.13, 73.39 ]
Total events: 1 (Any COX inhibitor), 0 (Other tocolytiic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI) 167 170 100.0 % 3.05 [ 0.13, 73.39 ]
Total events: 1 (Any COX inhibitor), 0 (Other tocolytiic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 2.25. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 25 Chorioamnionitis or endometritis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 25 Chorioamnionitis or endometritis
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
Schorr 1998 0/45 0/43 Not estimable
Subtotal (95% CI) 45 43 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 45 43 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.26. Comparison 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of
tocolytic), Outcome 26 Caesarean section delivery.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 2 Any COX inhibitors compared with any other tocolytic (subgrouped by type of tocolytic)
Outcome: 26 Caesarean section delivery
Study or subgroup Any COX inhibitor Other tocolytic Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Any COX inhibitors compared with any betamimetic agent
Subtotal (95% CI) 0 0 Not estimable
Total events: 0 (Any COX inhibitor), 0 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Any COX inhibitors compared with magnesium sulphate
McWhorter 2004 21/92 19/102 100.0 % 1.23 [ 0.70, 2.13 ]
Subtotal (95% CI) 92 102 100.0 % 1.23 [ 0.70, 2.13 ]
Total events: 21 (Any COX inhibitor), 19 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Total (95% CI) 92 102 100.0 % 1.23 [ 0.70, 2.13 ]
Total events: 21 (Any COX inhibitor), 19 (Other tocolytic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 3.1. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 1 Perinatal
mortality.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 1 Perinatal mortality
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sawdy 2003 0/20 0/10 Not estimable
Stika 2002 0/12 0/12 Not estimable
Total (95% CI) 32 22 Not estimable
Total events: 0 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.2. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 2 Respiratory
distress syndrome.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 2 Respiratory distress syndrome
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 1/12 1/12 100.0 % 1.00 [ 0.07, 14.21 ]
Total (95% CI) 12 12 100.0 % 1.00 [ 0.07, 14.21 ]
Total events: 1 (Any Non select. COX), 1 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.3. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 3
Intraventricular haemorrhage Grades III or IV.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 3 Intraventricular haemorrhage Grades III or IV
Study or subgroup Any non-select. COX Any COX-2 inhib Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 0/12 0/12 Not estimable
Total (95% CI) 12 12 Not estimable
Total events: 0 (Any non-select. COX), 0 (Any COX-2 inhib)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.4. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 4
Intraventricular haemorrhage - all grades.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 4 Intraventricular haemorrhage - all grades
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 1/12 2/12 100.0 % 0.50 [ 0.05, 4.81 ]
Total (95% CI) 12 12 100.0 % 0.50 [ 0.05, 4.81 ]
Total events: 1 (Any Non select. COX), 2 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 3.5. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 5 Necrotising
enterocolitis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 5 Necrotising enterocolitis
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 0/12 0/12 Not estimable
Total (95% CI) 12 12 Not estimable
Total events: 0 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.6. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 6 Interval from
treatment to delivery (subgrouped by interval).
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 6 Interval from treatment to delivery (subgrouped by interval)
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Delivery within or at 48 hours of initiation of treatment
Stika 2002 0/12 0/12 Not estimable
Subtotal (95% CI) 12 12 Not estimable
Total events: 0 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Delivery within 7 days of initiation of treatment
Stika 2002 1/12 0/12 100.0 % 3.00 [ 0.13, 67.06 ]
Subtotal (95% CI) 12 12 100.0 % 3.00 [ 0.13, 67.06 ]
Total events: 1 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 3.7. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 7 Gestation at
birth.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 7 Gestation at birth
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stika 2002 12 35.7 (3.3) 12 35.7 (3.7) 100.0 % 0.0 [ -2.81, 2.81 ]
Total (95% CI) 12 12 100.0 % 0.0 [ -2.81, 2.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 8 Birthweight.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 8 Birthweight
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Stika 2002 12 2547 (732) 12 2520 (709) 100.0 % 27.00 [ -549.58, 603.58 ]
Total (95% CI) 12 12 100.0 % 27.00 [ -549.58, 603.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 9 Apgar score
less than 7 at 5 minutes.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 9 Apgar score less than 7 at 5 minutes
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 1/12 0/12 100.0 % 3.00 [ 0.13, 67.06 ]
Total (95% CI) 12 12 100.0 % 3.00 [ 0.13, 67.06 ]
Total events: 1 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 3.10. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 10 Admission
to neonatal intensive care nursery.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 10 Admission to neonatal intensive care nursery
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sawdy 2003 6/20 3/10 80.0 % 1.00 [ 0.31, 3.19 ]
Stika 2002 1/12 1/12 20.0 % 1.00 [ 0.07, 14.21 ]
Total (95% CI) 32 22 100.0 % 1.00 [ 0.34, 2.91 ]
Total events: 7 (Any Non select. COX), 4 (Any COX-2 inhibitor)
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.11. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 11 Neonatal
mechanical ventilation.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 11 Neonatal mechanical ventilation
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 1/12 1/12 100.0 % 1.00 [ 0.07, 14.21 ]
Total (95% CI) 12 12 100.0 % 1.00 [ 0.07, 14.21 ]
Total events: 1 (Any Non select. COX), 1 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 3.12. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 12 Neonatal
sepsis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 12 Neonatal sepsis
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 0/12 1/12 100.0 % 0.33 [ 0.01, 7.45 ]
Total (95% CI) 12 12 100.0 % 0.33 [ 0.01, 7.45 ]
Total events: 0 (Any Non select. COX), 1 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 3.13. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 13 Maternal
adverse drug reaction.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 13 Maternal adverse drug reaction
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sawdy 2003 0/20 0/10 Not estimable
Stika 2002 0/12 0/12 Not estimable
Total (95% CI) 32 22 Not estimable
Total events: 0 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.14. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 14 Antepartum
haemorrhage.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 14 Antepartum haemorrhage
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 0/12 1/12 100.0 % 0.33 [ 0.01, 7.45 ]
Total (95% CI) 12 12 100.0 % 0.33 [ 0.01, 7.45 ]
Total events: 0 (Any Non select. COX), 1 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 3.15. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 15
Oligohydramnios.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 15 Oligohydramnios
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 4/12 1/12 100.0 % 4.00 [ 0.52, 30.76 ]
Total (95% CI) 12 12 100.0 % 4.00 [ 0.52, 30.76 ]
Total events: 4 (Any Non select. COX), 1 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
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Analysis 3.16. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 16 Premature
closure of the ductus arteriosus.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 16 Premature closure of the ductus arteriosus
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sawdy 2003 0/20 0/10 Not estimable
Stika 2002 0/12 0/12 Not estimable
Total (95% CI) 32 22 Not estimable
Total events: 0 (Any Non select. COX), 0 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.17. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 17
Chorioamnionitis or endometritis.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 17 Chorioamnionitis or endometritis
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 2/12 1/12 100.0 % 2.00 [ 0.21, 19.23 ]
Total (95% CI) 12 12 100.0 % 2.00 [ 0.21, 19.23 ]
Total events: 2 (Any Non select. COX), 1 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 3.18. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 18 Caesarean
section delivery.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 18 Caesarean section delivery
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Stika 2002 2/12 3/12 100.0 % 0.67 [ 0.13, 3.30 ]
Total (95% CI) 12 12 100.0 % 0.67 [ 0.13, 3.30 ]
Total events: 2 (Any Non select. COX), 3 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
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Analysis 3.19. Comparison 3 Indomethacin compared with any COX-2 inhibitors, Outcome 19 Preterm
birth before 37 weeks.
Review: Cyclo-oxygenase (COX) inhibitors for treating preterm labour
Comparison: 3 Indomethacin compared with any COX-2 inhibitors
Outcome: 19 Preterm birth before 37 weeks
Study or subgroup
Any Non
select.
COX
Any
COX-2
inhibitor Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Sawdy 2003 6/20 3/10 100.0 % 1.00 [ 0.31, 3.19 ]
Stika 2002 0/12 0/12 Not estimable
Total (95% CI) 32 22 100.0 % 1.00 [ 0.31, 3.19 ]
Total events: 6 (Any Non select. COX), 3 (Any COX-2 inhibitor)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
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